

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/586,426
Applicant: Mark R. Bush, et al
Filed: July 19, 2006
TC/A.U.: 1614
Examiner: Unknown
Docket No.: PC25862A
Customer No.: 28880
Title: Novel Imidazole-Based HMG-CoA Reductase Inhibitors

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Forms PTO/SB/08A and PTO/SB/08B are brought to the attention of the Examiner.

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 C.F.R. § 153(d); or before the mailing of the first Office Action on the merits.

In accordance with 37 C.F.R. § 198(a)(2), a copy of each document or other information listed on the enclosed Forms PTO/SB08A and PTO/SB/08B is provided, except for United States Patent Application Publications.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. § 102 and 103, and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art".

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Forms PTO/SB/08A and PTO/SB/08B, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

It is understood by the Applicants that this paper requires no fee, however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Dated: 4-19-07

Respectfully submitted,



Michelle A. Sherwood
Registration No. 36,271
Pfizer, Inc.
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-7295
Fax (734) 622-1553